Interpace Biosciences's Total Assets for the quarter that ended in Dec. 2024 was $14.79 Mil.
During the past 12 months, Interpace Biosciences's average Total Assets Growth Rate was 38.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -28.00% per year.
During the past 5 years, the average Total Assets Growth Rate was -29.40% per year.
During the past 10 years, the average Total Assets Growth Rate was -17.00% per year.
During the past 13 years, Interpace Biosciences's highest 3-Year average Total Assets Growth Rate was 187.20%. The lowest was -39.30%. And the median was -6.00%.
Interpace Biosciences Total Assets Historical Data
The historical data trend for Interpace Biosciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Interpace Biosciences's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (OTCPK:IDXG) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Interpace Biosciences's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Interpace Biosciences Total Assets Related Terms
Thank you for viewing the detailed overview of Interpace Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer, PancraGEN for pancreatic and biliary cancer, RespriDx for lung cancer, and BarreGEN for the detection of esophageal cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IDXG has been successfully added to your 